Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial.

ABSTRACT:

Introduction

Hypopharyngeal squamous cell carcinoma (HPSCC) has the poorest prognosis among head and neck cancer subtypes. The efficacy, role in organ preservation, safety, and biomarkers of induction immunochemotherapy for HPSCC require further investigation.

Methods

This phase II trial enrolled untreated patients with locally advanced (T1N + M0, T2-4N0-3M0) HPSCC. Induction therapy consisted of tislelizumab (200 mg), nab-paclitaxel (260 mg/m²), and cisplatin (75 mg/m²) i.v. on day 1 of each 3-week cycle for two cycles (ChiCTR2200060094). The primary endpoint was the larynx preservation rate (LPR) at 3 months. Secondary endpoints included objective response rate (ORR), pathological complete response (pCR) rate, disease control rate (DCR), larynx preser

SUBMITTER: Gui L 

PROVIDER: S-EPMC12314382 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature